Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

Next Previous
Search
Trial Profile

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Maridebart cafraglutide (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Acronyms MARITIME program; MARITIME-1
  • Sponsors Amgen

    • Most Recent Events

    • 05 Mar 2025 Status changed from planning to not yet recruiting.
    • 04 Feb 2025 According to an Amgen media release, trial expected to begin in H1 2025.
    • 26 Nov 2024 According to an Amgen media release, results from the phase 2 study have enabled the initiation of MARITIME, a Phase 3 program across obesity and a number of related conditions, providing a unique potential new treatment option for patients.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top